XML 34 R23.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Information | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Segment Information | Note 14 — Segment Information Abbott’s principal business is the discovery, development, manufacture, and sale of a broad line of healthcare products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, healthcare facilities, laboratories, physicians’ offices, and government agencies throughout the world. Abbott’s reportable segments are as follows: Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products. Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products. Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics, and Point of Care Diagnostics businesses are aggregated and reported as the Diagnostic Products segment. Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products. For segment reporting purposes, the Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation, and Diabetes Care businesses are aggregated and reported as the Medical Devices segment. Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. The chief operating decision maker (CODM) at Abbott is the Chief Executive Officer (CEO). The CODM primarily considers sales and operating margin to assess the performance of segments and to allocate resources, where segment operating margin profitability includes cost of products sold and operating expenses. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets. The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
|  | Net Sales to External Customers |  | Cost of Products Sold |  | Research and Development |  | Selling, General and Administrative |  | Operating Earnings
|  | Three Months Ended September 30, |  | Three Months Ended September 30, |  | Three Months Ended September 30, |  | Three Months Ended September 30, |  | Three Months Ended September 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024
Established Pharmaceuticals |  | $ | 1,511 |  |  | $ | 1,406 |  |  | $ | (714) |  |  | $ | (644) |  |  | $ | (42) |  |  | $ | (46) |  |  | $ | (364) |  |  | $ | (336) |  |  | $ | 391 |  |  | $ | 380 |
Nutritionals |  | 2,153 |  |  | 2,066 |  |  | (1,223) |  |  | (1,151) |  |  | (55) |  |  | (53) |  |  | (515) |  |  | (550) |  |  | 360 |  |  | 312 |
Diagnostics |  | 2,253 |  |  | 2,412 |  |  | (1,290) |  |  | (1,280) |  |  | (150) |  |  | (165) |  |  | (413) |  |  | (409) |  |  | 400 |  |  | 558 |
Medical Devices |  | 5,448 |  |  | 4,747 |  |  | (1,767) |  |  | (1,605) |  |  | (462) |  |  | (408) |  |  | (1,390) |  |  | (1,221) |  |  | 1,829 |  |  | 1,513 |
Total |  | $ | 11,365 |  |  | $ | 10,631 |  |  | $ | (4,994) |  |  | $ | (4,680) |  |  | $ | (709) |  |  | $ | (672) |  |  | $ | (2,682) |  |  | $ | (2,516) |  |  | $ | 2,980 |  |  | $ | 2,763 |
Other |  | 4 |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales |  | $ | 11,369 |  |  | $ | 10,635 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate functions and plan benefit costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (84) |  |  | (140) |
Net interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (44) |  |  | (51) |
Share-based compensation (a) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (120) |  |  | (117) |
Amortization of Intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (420) |  |  | (470) |
Other, net (b) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (132) |  |  | (45) |
Earnings before Taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 2,180 |  |  | $ | 1,940 |
|  | Net Sales to External Customers |  | Cost of Products Sold |  | Research and Development |  | Selling, General and Administrative |  | Operating Earnings
|  | Nine Months Ended September 30, |  | Nine Months Ended September 30, |  | Nine Months Ended September 30, |  | Nine Months Ended September 30, |  | Nine Months Ended September 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024
Established Pharmaceuticals |  | $ | 4,154 |  |  | $ | 3,926 |  |  | $ | (1,914) |  |  | $ | (1,819) |  |  | $ | (127) |  |  | $ | (131) |  |  | $ | (1,078) |  |  | $ | (1,014) |  |  | $ | 1,035 |  |  | $ | 962 |
Nutritionals |  | 6,511 |  |  | 6,284 |  |  | (3,502) |  |  | (3,387) |  |  | (161) |  |  | (158) |  |  | (1,676) |  |  | (1,677) |  |  | 1,172 |  |  | 1,062 |
Diagnostics |  | 6,480 |  |  | 6,821 |  |  | (3,666) |  |  | (3,671) |  |  | (455) |  |  | (482) |  |  | (1,228) |  |  | (1,206) |  |  | 1,131 |  |  | 1,462 |
Medical Devices |  | 15,712 |  |  | 13,934 |  |  | (5,123) |  |  | (4,779) |  |  | (1,293) |  |  | (1,155) |  |  | (4,062) |  |  | (3,620) |  |  | 5,234 |  |  | 4,380 |
Total |  | $ | 32,857 |  |  | $ | 30,965 |  |  | $ | (14,205) |  |  | $ | (13,656) |  |  | $ | (2,036) |  |  | $ | (1,926) |  |  | $ | (8,044) |  |  | $ | (7,517) |  |  | $ | 8,572 |  |  | $ | 7,866 |
Other |  | 12 |  |  | 11 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales |  | $ | 32,869 |  |  | $ | 30,976 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate functions and plan benefit costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (177) |  |  | (286) |
Net interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (143) |  |  | (170) |
Share-based compensation (a) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (551) |  |  | (562) |
Amortization of Intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (1,260) |  |  | (1,413) |
Other, net (b) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (333) |  |  | (452) |
Earnings before Taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 6,108 |  |  | $ | 4,983 |
______________________________________
(a) | Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b) | Other, net for the three and nine months ended September 30, 2025 and 2024, includes charges related to restructurings. For the nine months ended September 30, 2025, Other, net includes a fair value adjustment to a contingent consideration. Other, net for the three and nine months ended September 30, 2024, includes charges related to impairment of IPR&D and costs related to business integration. Other, net for the nine months ended September 30, 2024, includes a loss on the divestiture of a non-core business.
|  | Depreciation |  | Additions to Property and Equipment
|  | Three Months Ended September 30, |  | Three Months Ended September 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Established Pharmaceuticals |  | $ | 28 |  |  | $ | 23 |  |  | $ | 38 |  |  | $ | 52 |
Nutritionals |  | 47 |  |  | 38 |  |  | 71 |  |  | 106 |
Diagnostics |  | 136 |  |  | 129 |  |  | 168 |  |  | 183 |
Medical Devices |  | 97 |  |  | 87 |  |  | 140 |  |  | 151 |
Total Reportable Segments |  | 308 |  |  | 277 |  |  | 417 |  |  | 492 |
Other |  | 63 |  |  | 54 |  |  | 70 |  |  | 77 |
Total |  | $ | 371 |  |  | $ | 331 |  |  | $ | 487 |  |  | $ | 569 |
|  | Depreciation |  | Additions to Property and Equipment
|  | Nine Months Ended September 30, |  | Nine Months Ended September 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Established Pharmaceuticals |  | $ | 76 |  |  | $ | 71 |  |  | $ | 110 |  |  | $ | 118 |
Nutritionals |  | 133 |  |  | 116 |  |  | 231 |  |  | 282 |
Diagnostics |  | 397 |  |  | 387 |  |  | 469 |  |  | 475 |
Medical Devices |  | 279 |  |  | 261 |  |  | 441 |  |  | 444 |
Total Reportable Segments |  | 885 |  |  | 835 |  |  | 1,251 |  |  | 1,319 |
Other |  | 179 |  |  | 163 |  |  | 192 |  |  | 194 |
Total |  | $ | 1,064 |  |  | $ | 998 |  |  | $ | 1,443 |  |  | $ | 1,513 |
|  | Total Assets
(in millions) |  | As of September 30, 2025 |  | As of December 31, 2024
Established Pharmaceuticals |  | $ | 3,730 |  |  | $ | 3,087 |
Nutritionals |  | 4,891 |  |  | 4,404 |
Diagnostics |  | 8,201 |  |  | 7,678 |
Medical Devices |  | 10,576 |  |  | 9,472 |
Total Reportable Segment Assets |  | $ | 27,398 |  |  | $ | 24,641 |
Cash and investments |  | 8,684 |  |  | 8,853 |
Goodwill and intangible assets |  | 29,569 |  |  | 29,755 |
All other (c) |  | 18,530 |  |  | 18,165 |
Total Assets |  | $ | 84,181 |  |  | $ | 81,414 |
(c) | As of September 30, 2025, and December 31, 2024, all other includes the long-term assets associated with the defined benefit plans and certain deferred tax assets.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration